Mineralys Therapeutics (MLYS) Earnings Date & Reports

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

MLYS is expected to report earnings to rise 34.18% to -105 cents per share on August 11

Mineralys Therapeutics MLYS Stock Earnings Reports

Q2'25

Est.

$-1.06

Q1'25

Beat

by $0.29

Q4'24

Missed

by $0.27

Q3'24

Missed

by $0.42

Q2'24

Missed

by $0.11

The last earnings report on May 12 showed earnings per share of -79 cents, beating the estimate of -108 cents. With 2.23M shares outstanding, the current market capitalization sits at 893.55M.

View a ticker or compare two or three

Compare

MLYS